---
title: 'The Niche Episode 043 – Charles River, IQVIA, Agios, Alloy'
type: 'episode'
url: 'https://doc.social/episodes/the-niche-episode-043-charles-river-iqvia-agios-alloy'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2021-04-05'
audio: 'unavailable — the host retired the file'
---

# The Niche Episode 043 – Charles River, IQVIA, Agios, Alloy

Charles River acquires Retrogenix, IQVIA fully acquires Q2 Solutions, Agios sells $1.8B in oncology, and Alloy forges a $75M series C. Sponsorshttps://www.thescopemethod.com Story Referenceshttps://tinyurl.com/Niche-043-1https://tinyurl.com…

## Summary

Charles River acquires Retrogenix, IQVIA fully acquires Q2 Solutions, Agios sells $1.8B in oncology, and Alloy forges a $75M series C.

**Sponsors
**[https://www.thescopemethod.com](https://www.thescopemethod.com)

**Story References
**[https://tinyurl.com/Niche-043-1](https://tinyurl.com/Niche-043-1)
[https://tinyurl.com/Niche-043-2](https://tinyurl.com/Niche-043-2)
[https://tinyurl.com/Niche-043-3](https://tinyurl.com/Niche-043-3)
[https://tinyurl.com/Niche-043-4](https://tinyurl.com/Niche-043-4)
[https://tinyurl.com/Niche-043-5](https://tinyurl.com/Niche-043-5)

**
Music by Luke Goodson
**[https://www.soundcloud.com/lukegoodson](https://www.soundcloud.com/lukegoodson)

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.